Compare BEKE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEKE | UTHR |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | China | United States |
| Employees | 135072 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 20.4B |
| IPO Year | 2020 | 1999 |
| Metric | BEKE | UTHR |
|---|---|---|
| Price | $16.48 | $500.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $24.36 | ★ $520.00 |
| AVG Volume (30 Days) | ★ 4.4M | 307.6K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $5.37 | $8.56 |
| Revenue Next Year | $2.18 | $10.71 |
| P/E Ratio | $41.26 | ★ $18.21 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $15.26 | $266.98 |
| 52 Week High | $25.17 | $537.19 |
| Indicator | BEKE | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 56.75 |
| Support Level | $16.14 | $463.06 |
| Resistance Level | $17.67 | $516.36 |
| Average True Range (ATR) | 0.44 | 17.02 |
| MACD | -0.18 | 3.90 |
| Stochastic Oscillator | 5.11 | 50.18 |
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.